A Phase 3 interventional study of Carbetocin and Placebo in Hyperphagia in Prader-Willi Syndrome, sponsored by ACADIA Pharmaceuticals Inc.. Completed at 30 sites in 6 countries. Open to participants aged 5 Years to 30 Years. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by ACADIA Pharmaceuticals Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Prader-Willi Syndrome with a site in United States — 9 open to participants now, 14 under way, 3 of them phase 3. Prader-Willi Syndrome · United States.
Among the 69 studies in Prader-Willi Syndrome with a site in United States, this one is the 2nd largest by enrollment of the 58 interventional ones that give a count, is one of 7 that started in 2023, is one of 14 in phase 3, and was the 58th registered.
144 studies on the registry are indexed under Prader-Willi Syndrome; 23 are open to participants now.
Browse Prader-Willi Syndrome studies →9 of the 69 studies in Prader-Willi Syndrome with a site in United States are open now. Recruiting first, the newest first:
Children's Mercy Hospital Kansas City · Sites in United States
Ages 13–17
ConSynance Therapeutics · Sites in United States
Ages 13–50
Grace Kim · Sites in United States
Ages 18–26
University of North Carolina, Chapel Hill · Sites in United States
Ages 18+ · Healthy volunteers
Harmony Biosciences Management, Inc. · Sites in United States, Australia, Belgium and 10 more countries
Ages 6+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 16 Prader-Willi Syndrome studies recruiting now, 7 (44%) set no upper age limit and 9 (56%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.
This study: 5 Years to 30 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 23 · Phase 3 16 · Phase 4 3
First in 1999; this study’s year is marked. 7 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 175 is above the median of 30 across 99 interventional studies indexed under Prader-Willi Syndrome.
Median enrollment 23 across the 58 interventional studies, 200 across the 11 observational. Of the 51 that completed or were terminated, 21 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 69 have an industry lead sponsor. The 10 most frequent:
ACADIA Pharmaceuticals Inc. is the lead sponsor of 41 studies on the registry; 5 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 24 (92%) have results posted.
ACADIA Pharmaceuticals Inc. has 3 studies filed under Prader-Willi Syndrome — fewer than ten, so there is no comparison to draw.
7 of the studies in Prader-Willi Syndrome with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06366464Phase 3Harmony Biosciences Management, Inc.A Study of Pitolisant in Patients With Prader-Willi Syndrome | 2027-04 |
| NCT06144645Phase 3Foundation for Prader-Willi ResearchA Clinical Evaluation of Non-Invasive Vagus Nerve Stimulation for Temper Outbursts in People With PWS | 2027-04-01 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT06239116Rhythm Pharmaceuticals, Inc.A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment | 2027-05-07 |
| NCT07348601ConSynance TherapeuticsA Study of CSTI-500 in Patients With Prader-Willi Syndrome | 2027-06 |
Add all 7 to your calendar (.ics) → With an account.
Among the 69 studies in Prader-Willi Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
12-week, randomized, double-blind, placebo-controlled, parallel-group study of carbetocin nasal spray for the treatment of hyperphagia in Prader-Willi syndrome (PWS)
This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study comparing carbetocin nasal spray 3.2 mg TID with placebo (matched placebo nasal spray TID) in subjects with PWS.
The criteria were revised on the registry on Oct 15, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Additional inclusion and exclusion criteria apply. Participants will be evaluated at Screening to ensure all eligibility requirements are met.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Carbetocin nasal spray 3.2 mg administered TID
Drug: Carbetocin
Matching placebo nasal spray administered TID
Drug: Placebo
Carbetocin nasal spray 3.2 mg administered TID
Also known as: ACP-101
Matching placebo nasal spray administered TID
Change From Baseline at Week 12 in Hyperphagia Questionnaire for Clinical Trials (HQ-CT) Score
The HQ-CT is a caregiver-reported, 9-item assessment of observable hyperphagia-related behaviors in participants with PWS. The questionnaire is administered to the caregiver by a trained rater using standardized prompts, and the same caregiver is expected to complete the assessment throughout the study whenever possible. Each item is scored from 0 to 4, resulting in a total score ranging from 0 to 36, with higher scores indicating greater severity of hyperphagia. A decrease from baseline reflects improvement, and a reduction of 7.7 points has been identified as a clinically meaningful within-participant improvement.
Time frame: Baseline to Week 12
Change From Baseline at Week 12 in Clinical Global Impression of Severity (CGI-S) for PWS Score
The CGI-S for PWS is a clinician-rated assessment of the overall severity of PWS symptoms at the time of evaluation. The CGI-S is rated on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most severely ill participants), with higher scores indicating greater illness severity. The assessment is performed by the Investigator or a trained, qualified designee, and the same rater is expected to evaluate a given participant throughout the study whenever possible to maintain rating consistency.
Time frame: Baseline to Week 12
Clinical Global Impression of Change (CGI-C) for PWS Score at Week 12
The CGI-C for PWS is a clinician-rated assessment of change in the overall severity of PWS symptoms relative to Baseline. The CGI-C is rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse), with lower scores indicating greater improvement from Baseline. The assessment is performed by the Investigator or a trained, qualified designee, and the same rater is expected to evaluate a given participant throughout the study whenever possible to maintain rating consistency.
Time frame: Week 12
Percentage of Subjects With Treatment Response at Week 12 (Defined as Improvement From Baseline ≥8 Points) Based on the HQ-CT Score at Week 12
Treatment response was defined as an improvement from Baseline of at least 8 points in the HQ-CT total score at Week 12. The HQ-CT is a caregiver-reported, 9-item assessment of observable hyperphagia-related behaviors in participants with PWS. Total scores range from 0 to 36, with higher scores indicating greater severity of hyperphagia. Participants meeting the ≥8-point improvement threshold were classified as responders.
Time frame: Week 12
Change From Baseline at Week 12 in CGI-S for Hyperphagia in PWS Score
The CGI-S for PWS is a clinician-rated assessment of the overall severity of PWS symptoms at the time of evaluation. The CGI-S is rated on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most severely ill participants), with higher scores indicating greater illness severity. The assessment is performed by the Investigator or a trained, qualified designee, and the same rater is expected to evaluate a given participant throughout the study whenever possible to maintain rating consistency.
Time frame: Baseline to Week 12
| Milestone | Carbetocin | Placebo |
|---|---|---|
| Started | 85 | 90 |
| Completed | 82 | 86 |
| Not completed | 3 | 4 |
The HQ-CT is a caregiver-reported, 9-item assessment of observable hyperphagia-related behaviors in participants with PWS. The questionnaire is administered to the caregiver by a trained rater using standardized prompts, and the same caregiver is expected to complete the assessment throughout the study whenever possible. Each item is scored from 0 to 4, resulting in a total score ranging from 0 to 36, with higher scores indicating greater severity of hyperphagia. A decrease from baseline reflects improvement, and a reduction of 7.7 points has been identified as a clinically meaningful within-participant improvement.
| Score on a scale | Carbetocin | Placebo |
|---|---|---|
| Change From Baseline at Week 12 in Hyperphagia Questionnaire for Clinical Trials (HQ-CT) Score | -4.8 ± 0.78 | -5.1 ± 0.75 |
The CGI-S for PWS is a clinician-rated assessment of the overall severity of PWS symptoms at the time of evaluation. The CGI-S is rated on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most severely ill participants), with higher scores indicating greater illness severity. The assessment is performed by the Investigator or a trained, qualified designee, and the same rater is expected to evaluate a given participant throughout the study whenever possible to maintain rating consistency.
| Score on a scale | Carbetocin | Placebo |
|---|---|---|
| Change From Baseline at Week 12 in Clinical Global Impression of Severity (CGI-S) for PWS Score | -0.4 ± 0.10 | -0.5 ± 0.10 |
The CGI-C for PWS is a clinician-rated assessment of change in the overall severity of PWS symptoms relative to Baseline. The CGI-C is rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse), with lower scores indicating greater improvement from Baseline. The assessment is performed by the Investigator or a trained, qualified designee, and the same rater is expected to evaluate a given participant throughout the study whenever possible to maintain rating consistency.
| Score on a scale | Carbetocin | Placebo |
|---|---|---|
| Clinical Global Impression of Change (CGI-C) for PWS Score at Week 12 | 3.6 ± 0.12 | 3.6 ± 0.12 |
Treatment response was defined as an improvement from Baseline of at least 8 points in the HQ-CT total score at Week 12. The HQ-CT is a caregiver-reported, 9-item assessment of observable hyperphagia-related behaviors in participants with PWS. Total scores range from 0 to 36, with higher scores indicating greater severity of hyperphagia. Participants meeting the ≥8-point improvement threshold were classified as responders.
| Participants | Carbetocin | Placebo |
|---|---|---|
| Percentage of Subjects With Treatment Response at Week 12 (Defined as Improvement From Baseline ≥8 Points) Based on the HQ-CT Score at Week 12 | 25 | 32 |
The CGI-S for PWS is a clinician-rated assessment of the overall severity of PWS symptoms at the time of evaluation. The CGI-S is rated on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most severely ill participants), with higher scores indicating greater illness severity. The assessment is performed by the Investigator or a trained, qualified designee, and the same rater is expected to evaluate a given participant throughout the study whenever possible to maintain rating consistency.
| Score on a scale | Carbetocin | Placebo |
|---|---|---|
| Change From Baseline at Week 12 in CGI-S for Hyperphagia in PWS Score | -0.7 ± 0.12 | -0.7 ± 0.12 |
Collected over From first dose of study drug through 30 days after the last dose (end of safety follow-up), up to approximately 16 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Carbetocin | 0/83 (0%) | 0/83 (0%) | 11/83 (13.3%) |
| Placebo | 0/88 (0%) | 0/88 (0%) | 9/88 (10.2%) |
| Event | Carbetocin | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 6/83 | 3/88 |
| PyrexiaGeneral disorders | 5/83 | 1/88 |
| DiarrheaGastrointestinal disorders | 2/83 | 5/88 |
Baseline characteristics are reported for enrolled participants with PWS only. Caregivers participated as informants for caregiver-reported study assessments and were not enrolled study participants, were not randomized, and are not included in baseline characteristic summaries.
| Age, Customized(Participants) | Carbetocin | Placebo | Total |
|---|---|---|---|
| <12 years | 40 | 41 | 81 |
| ≥12 to <17 years | 20 | 23 | 43 |
| ≥17 years | 25 | 26 | 51 |
| Sex: Female, Male(Participants) | Carbetocin | Placebo | Total |
|---|---|---|---|
| Female | 46 | 59 | 105 |
| Male | 39 | 31 | 70 |
| Race (NIH/OMB)(Participants) | Carbetocin | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 3 | 2 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 2 | 3 |
| White | 71 | 81 | 152 |
| More than one race | 6 | 2 | 8 |
| Unknown or Not Reported | 3 | 3 | 6 |
| Ethnicity (NIH/OMB)(Participants) | Carbetocin | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 11 | 6 | 17 |
| Not Hispanic or Latino | 70 | 77 | 147 |
| Unknown or Not Reported | 4 | 7 | 11 |
| Prior Carbetocin Use(Participants) | Carbetocin | Placebo | Total |
|---|---|---|---|
| Yes | 13 | 15 | 28 |
| No | 72 | 75 | 147 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2023 to primary completion in Aug 2025, 20 months.
Results were first posted in Oct 2026, 1 year 1 month after primary completion.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Oct 2025 → Aug 2025 and completion Nov 2025 → Aug 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Carbetocin